

Oncomed Pharmaceuticals (OMED : US\$21.0)

Oncomed Pharmaceuticals tumbles 28% in 2014, underperforming 87% of the market

Oncomed Pharmaceuticals Inc, NASDAQ's 7th largest biotechnology company by market cap, has now tumbled US\$8.32 (or 28.4%) year to date in 2014 to close at US\$21.0. This loss means the stock has underperformed 87% of NASDAQ-listed stocks in 2014. The volume YTD has been 0.9 times average trading of 205,385 shares. Compared with the NASDAQ-100 Index which has risen 9.8% YTD, this represents a relative price change of -38.2%. In 2014 the market cap has declined US\$196.9 million.

Introduction

We are currently bearish on this stock, both in the short-term based on technical indicators, as well as in the long-term based on fundamental metrics

What makes us most bearish on the stock is the following:

- Its Moving Average Convergence Divergence indicators are falling, with its 12-day EMA lower than its 26-day EMA.
- Amongst stocks that are shorted, it was in the top quartile as a percentage of stock shorted, suggesting that there are many confident bears of the stock.
- The price to 200-day MAP ratio is 0.69, a bearish indicator.

However, there are some reasons why some in the market are more bullish on the stock:

- In the last three months the number of rises outnumbered falls 33:30 or 1.1:1.
- The Price to Book of 5.2 lower than average of 5.3 for the Biotechnology sector and 6.1 for the Total NASDAQ Market.

Stock Summary

Sector	Biotechnology
Market Cap	US\$619.1 million
Shares Outstanding	29,480,494
ISIN	US68234X1028
Relative Strength (3 mo)	13

MCap: A Historical Perspective

	Share Price (USD)	Market Cap (\$)
Last	21.0	619.1 million

Analysis

Bearish Signals

- In the last 17 trading sessions there has been a net decline of 16.03%; the stock has retreated eleven times and the biggest one day decline was 6.5% on Jul 07.
- In the NASDAQ market of 2,403 stocks traded today, the stock has a 6-month relative strength of 7 indicating it is trailing 93.0% of the market.
- The Moving Average Convergence Divergence (MACD) indicator of 12-day Exponential Moving Average (EMA) of 22.07 minus the 26-day EMA of 22.75 is negative suggesting a bearish signal. Both the 12-day EMA as well as the 26-day EMA are falling, another bearish signal.
- In the past 200 days this ratio has been under 0.69 just once suggesting a support level. The 200-day MAP has decreased to US\$30.44. A decrease is another bearish indicator.
- The price to 200-day MAP ratio is 0.69, a bearish indicator.
- The bears are maintaining control with price open, high, low and close being below yesterday's levels.
- In the NASDAQ Short Selling market of 2437 stocks, short selling as a % of issued shares ranked 589th and within the top quartile of stocks. This means it was higher than market average of 0.45%, a bearish indicator.
- The current short volume is 1.1 times its own historical average of 0.5%.

Other Bearish Signals:

- Net Profit margin is negative in recent quarters.

Quarterly Trend:

[Quarter ended, all figures in %]:

Qtr	Revenue Growth	Net Profit Margin
Mar 14	-	-230.6
Dec 13	46.8	-22.9
Mar 13	-80	-293.2
Jun 12	-	-
Mar 12	-	-

The stock has a score of merely 2 out of 9 set by Joseph Piotroski [pass mark >=5]:

Positive operating cashflow; improvement in current ratio from 3.5 to 5.1.

Bearish Indicators and Rank in Market:

Description	Value	Rank In Market
Price to Book Value	5.2	In Bottom Quartile
Annual Revenue	US\$37.8 million	In Bottom Quartile
Price/MAP50	0.6	In Bottom 8%
Volatility %	7.8	In Bottom 8%
Price/MAP200	0.69	In Bottom 8%
Relative Strength (6M)	7	In Bottom 6%
Price Change %	-4.8	In Bottom 5%
Price to Sales	16.4	In Bottom 1%

Note

Neutral Indicators and Rank in Market:

Description	Value	Rank In Market
Turnover in Quarter	US\$210.4 million	In 2nd Quartile
MCap	US\$619.1 million	In 2nd Quartile

Bullish Signals:

- The price is at a discount of 9.2% to the 1-month volume weighted average price of US\$23.12, which may appeal as a value proposition.
- The Price/MAP of 0.69 for OMED is higher than the Price/MAP for the NASDAQ-100 Index of 0.4.

Undervaluation:

- The Price to Book of 5.2 lower than average of 5.3 for the Biotechnology sector and 6.1 for the Total NASDAQ Market.
- The company is cash rich with Cash to Market Capitalisation at 33.7%.
- The Q Ratio, defined by James Tobin as MCap divided by Total Assets, is 1.9. Compared with the rest of the market the stock is undervalued.

Other Bullish Signals:

- Net Profit margin is negative but improving in recent years.


Analysis (continued)

Annual Trend:

[Year ended, all figures in %]:

Year	Net Profit Margin	EBIT Margin	EBITDA Margin
Dec 13	-69	-	-
Dec 12	-90.1	-90.1	-83.9

% Growth Y.O.Y, Revenue & Net Profit




Also, the following criteria set by Benjamin Graham:

- "Current ratio of two or more"; current assets are 5.1 times current liabilities.

Bullish Indicators and Rank in Market:

Description	Value	Rank In Market
Cash to MCap %	33.7	In Top 9%


Revenue Share Biotechnology



Insider Trades




Turnover Rate & Turnover Period



Trailing 3 months

Turnover	US\$210.4 million
Volume	8,851,222
Volume Index (1 is avg)	0.7


YTD Comparison Stock Sector Index




Price Volume Trend: Trailing Quarter



Weekly Price Volume Dynamics (Last 12 Weeks)



Stock v Index (Trailing Year)



Price/Moving Average Price [P/MAP]



Peer Group Analysis

Sector sorting

Name	Last Price	Relative strength (6-months)	MCap (Millions)	PV \$1000 (1 yr)	Revenue (Millions)	Net Profit (Millions)	Total Assets (Millions)
Bluebird Bio	32.73	95	802	-	20	-25	224
Oncomed Pharmaceuticals	21.0	7	619	-	38	-26	334
Zeltiq Aesthetics	15.24	18	567	2,493	123	-19	-
Aratana Therapeutics	13.76	15	405	-	1	-4	116
Prosensa Holding	9.45	98	331	-	14	-23	123

Recent Analyst Recommendations

Date	Brokerage	Action	Past Rating	Current Rating	Prev Target	Price Target
13-Jun-2014	Mizuho	Reiterated Rating	-	Buy	-	-
13-May-2014	Zacks	Upgrade	Underperform	Neutral	-	23.1
09-May-2014	Jefferies Group	Lower Price Target	-	-	50	48

Reported Buying Selling by Insiders

Insider	Date	Transaction Type	No. of Shares	Price, US\$	Value, US\$
Lewicki John A.	Jul 01, 2014	Sold	4,000	24.06	96,240
Pollard-knight Denise	Jun 30, 2014	Sold	11,485	23.59	270,931
Dupont Jakob	Jun 26, 2014	Sold	1,500	23	34,500
Pollard-knight Denise	Jun 25, 2014	Sold	3,252	23.56	76,617
Pollard-knight Denise	Jun 24, 2014	Sold	11,764	23.57	277,277
Pollard-knight Denise	Jun 23, 2014	Sold	52,797	24.2	1,277,687
Gurney Austin	Jun 17, 2014	Sold	4,000	24.99	99,960
Root Jonathan D	Jun 09, 2014	Sold	8,252	24.62	203,164
Root Jonathan D	Jun 10, 2014	Sold	4,800	24.48	117,504
Hoey Timothy	May 05, 2014	Sold	2,500	26.41	66,025

Company Overview

Activities

OncoMed Pharmaceuticals Inc. provides biotechnology research and development. The Company synthesizes oncogenic mutations in stem cells that allows the cells to grow without normal limitations in attempts to exploit therapies that selectively target tumor initiating cells. OncoMed serves the healthcare industry and cancer therapy patients.

Further details can be found at
www.oncomed.com.

Regulatory Announcements

To view Recent Company Headlines, [click here](#)

July 03: Oncomed Pharmaceuticals insider sells; shares at an 11-day high
July 02: Oncomed Pharmaceuticals insider sells; shares at a five-day high
July 02: OncoMed Pharmaceuticals Granted Broad FZD-Fc Composition-of-Matter and Use Patent in U.S.
June 30: Oncomed Pharmaceuticals insider sells
June 19: Oncomed Pharmaceuticals: Submission of Matters to a Vote of Security Holders
June 19: OncoMed Pharmaceuticals to Present at the 9th Annual JMP Securities Healthcare Conference
June 18: OncoMed Provides Update on FZD8-Fc (OMP-54F28) Phase I Clinical Trials

To view 8-K people news for Oncomed-

Pharmaceuticals, [click here](#)

June 19: Oncomed Pharmaceuticals Elects 2 Directors
March 17: William Waddill - Oncomed Pharmaceuticals CFO resigns
March 17: William Waddill - Oncomed Pharmaceuticals senior vice president resigns


Issued Capital

Based on 29,480,494 issued equity shares the market capitalisation is US\$619.1 million. It is NASDAQ's 4th largest Biotechnology company by total revenue.
The top sixteen shareholders hold 11.2% of the issued capital leaving a float of 88.8%.

Top 10 Shareholders

Name of Shareholder	No. of Shares	% Held
Sectoral Asset Management Inc	1,347,642	4.57
Columbus Circle Investors	696,550	2.36
Primecap Management Co/Ca/	340,700	1.16
Franklin Resources Inc	236,800	0.8
Vanguard Group Inc	150,548	0.51
Bank Of America Corp /De/	93,172	0.32
Barclays Global Investors Uk Holdings Ltd	76,150	0.26
State Street Corp	72,285	0.25
Deutsche Bank Ag\	67,773	0.23
Eventide Asset Management Llc	52,800	0.18
Total	3,134,420	10.63

Top 16 Institutional Holdings



Board and Management

Paul J. Hastings
CEO & Chairman



Mr. Hastings is the President and CEO of OncoMed Pharmaceuticals. Prior to joining OncoMed in 2006, Mr. Hastings was President and Chief Executive Officer of QLT, Inc. Previous to that, Mr. Hastings served as President and Chief Executive Officer of Axys Pharmaceuticals, which was acquired by Celera Corporation in 2001. From 1999 to 2001, Mr. Hastings served as the President of Chiron BioPharmaceuticals, a division of Chiron Corporation. Prior to that, he was President and Chief Executive Officer of LXR Biotechnology. Mr. Hastings also held a series of management positions of increasing responsibility at Genzyme Corporation, including serving as President of Genzyme Therapeutics Europe as well as President, Genzyme Therapeutics. Mr. Hastings also served as Vice President, Marketing and Sales and General Manager, Europe for Synergen, Inc., and previously held a series of marketing and sales management positions with Hoffmann-La Roche.

Mr. Hastings was recently Chairman of the Board of Proteolix (sold to Onyx Pharmaceuticals in 2010), and served on the boards of ViaCell (sold to Perkin-Elmer in 2007). He is currently on the boards of Pacira Pharmaceuticals and Relypsa and serves as Chairman of the Emerging Companies Section of the Biotechnology Industry Organization, and was Chairman of the Bay Area Biosciences Association (BayBio). Mr. Hastings received a Bachelor of Science degree in pharmacy from the University of Rhode Island.

Sunil Patel
CFO & Senior Vice President

Mr. Patel, age 42, has served as our Senior Vice President, Chief Business Officer since December 2012 and previously served as our Senior Vice President, Corporate Development since July 2009. From September 2008 to June 2009, Mr. Patel served as the Vice President of Corporate Development & Marketing at BiPar Sciences Inc., a privately-held biotechnology company that focused on the development of cancer therapies and was acquired by Sanofi-Aventis S.A. in 2009. From May 2007 to August 2008, Mr. Patel served as the Vice President of Corporate Development at Allos Therapeutics, Inc., a publicly-traded biopharmaceutical company focused on the development and commercialization of cancer therapeutics. Prior to that time, Mr. Patel held corporate development, marketing, and strategy positions with Connetics Corporation, Abgenix, Inc. and Gilead Sciences, Inc. Mr. Patel also previously worked as a consultant with McKinsey & Company from 1998 to 2003. Since October 2010, Mr. Patel has served on the board of directors of Ligand Pharmaceuticals, Inc., a publicly-traded biotechnology company. Mr. Patel received a B.S. in Chemistry from the University of California Berkeley and an M.S. in Molecular Bioengineering/Biotechnology from the University of Washington.

Creation of shareholder value in Oncomed Pharmaceuticals:

Since appointment as CFO: The present value of USD1,000 invested on the appointment date of March 18, 2014 at close price of US\$34.92 is US\$601, for a capital loss of US\$399.

Michael Wyzga
Director

Mr. Wyzga is currently President and Chief Executive Officer of Radius Health, Inc. Prior to joining Radius, Mr. Wyzga was Executive Vice President, Finance and Chief Financial Officer of Genzyme Corporation until its acquisition by Sanofi in April 2011. Mr. Wyzga joined Genzyme in 1998 and held primary responsibility for the company's financial management worldwide. He provided key leadership in the successful \$20.1 billion sale of Genzyme to Sanofi, which was the second-largest acquisition in biotechnology history. Prior to joining Genzyme, Mr. Wyzga was Chief Financial Officer of Sovereign Hill Software. He previously served as Vice President of Finance and Chief Financial Officer of CacheLink Corporation, a client/service software company. Mr. Wyzga also held management positions at Lotus Development Corporation and Digital Equipment Corporation. He received an MBA from Providence College and a BS from Suffolk University.

Creation of shareholder value in Oncomed Pharmaceuticals:

Since appointment as Director: The present value of USD1,000 invested on the appointment date of October 17, 2013 at close price of US\$14.56 is US\$1,442, for a capital gain of US\$442.

Board and Management (continued)

John Lewicki Executive Vice President

From 1983 to 2000, John Lewicki served in various capacities at Scios, Inc., where he managed the company's research organization across diverse therapeutic areas. Among his many achievements with that organization was the co-discovery of Natrecor[®], an FDA approved drug for congestive heart failure. Most recently, Dr. Lewicki was Senior Vice President, Research and Development of an early-stage biotechnology company working in the infectious disease field.

Jakob Dupont Senior Vice President

Dr. Dupont is a medical Oncologist with extensive academic and pharmaceutical oncology drug development experience. He joined OncoMed from Genentech, a member of the Roche Group, where he was Global Medical Director for Avastin[®] (bevacizumab). While at Genentech, Dr. Dupont held leadership positions at all stages of oncology drug development from Phase I through Phase IV. Most recently, Dr. Dupont oversaw the global medical strategy and late-stage medical program for Avastin. In that role, he managed an international team of global medical leaders, worked closely with the business team on brand planning, and served as an Avastin spokesperson to the global investment community.

Financial Results (Quarterly)

31 March, 2014

INCOME STATEMENT

Currency in Thousand of USD	2014-03-31	2013-03-31	Change %
Revenue:			
Collaboration revenue related party		493	
Collaboration revenue	6,015	2,439	Up 146.6
Total revenue	6,015	2,932	Up 105.2
Operating expenses:			
Research and development	16,709	9,576	Up 74.5
General and administrative	3,213	1,985	Up 61.9
Total operating expenses	19,922	11,561	Up 72.3
Loss from operations	-13,907	-8,629	Deterioration 61.2
Interest and other income, net	36	31	Up 16.1
Net loss	-13,871	-8,598	Deterioration 61.3
Net loss per common share, basic and diluted	-47.0c	-792.0c	Reduced 94.1
Shares used to compute net loss per common share, basic and diluted	29,443,230	1,084,944	Up 2,613.8

BALANCE SHEET

Currency in Thousand of USD	2014-03-31	2013-12-31	Change %
Assets			
Current assets:			
Cash and cash equivalents	25,950	208,931	Down 87.6
Short-term investments	257,963	107,263	Up 140.5
Receivables - related parties	23	23	Steady
Prepaid and other current assets	2,502	2,527	Down 1.0
Total current assets	286,438	318,744	Down 10.1
Property and equipment, net	4,962	4,641	Up 6.9
Other assets	10,486	10,300	Up 1.8
Total assets	301,886	333,685	Down 9.5
Liabilities and Stockholders' Equity			
Current liabilities:			
Accounts payable	2,935	5,706	Down 48.6
Income tax payable		10,758	
Accrued liabilities	10,064	9,860	Up 2.1
Current portion of deferred revenue	35,059	35,059	Steady
Current portion of deferred rent	637	624	Up 2.1
Liability for shares issued with repurchase rights	10	10	Steady
Total current liabilities	48,705	62,017	Down 21.5
Deferred revenue, less current portion	142,856	148,871	Down 4.0
Deferred rent, less current portion	2,980	3,146	Down 5.3
Non-current income tax payable	1,517	1,515	Up 0.1
Liability for shares issued with repurchase rights, less current portion	11	14	Down 21.4
Total liabilities	196,069	215,563	Down 9.0
Commitments and contingencies			

Financial Results (Quarterly) (continued)

31 March, 2014

Stockholders' equity:

Preferred stock, 0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding at March 31, 2014 and December 31, 2013

Common stock, 0.001 par value; 145,000,000 shares authorized at March 31, 2014 and December 31, 2013; 29,538,650 shares and 29,397,964 shares issued and outstanding at March 31, 2014 and December 31, 2013, respectively	30	29	Up 3.4
--	----	----	--------

Additional paid-in capital	294,113	292,505	Up 0.5
----------------------------	---------	---------	--------

Accumulated other comprehensive income (loss)	-29	14	Deterioration
---	-----	----	---------------

Accumulated deficit	-188,297	-174,426	Deterioration 8.0
---------------------	----------	----------	-------------------

Total stockholders' equity	105,817	118,122	Down 10.4
----------------------------	---------	---------	-----------

Total liabilities and stockholders' equity	301,886	333,685	Down 9.5
--	---------	---------	----------

BuySellSignals Financial Research provides equity research on over 48,000 companies listed in more than 90 countries and 120 markets across the world. BuySellSignals believes that every stock has a story to tell and that this story changes every day. To capture this story, BuySellSignals offers the latest pertinent and comprehensive information so that investors can make well-informed investment decisions.

BuySellSignals publishes equity research reports on each stock, sector and index daily to capture the latest market movements and sentiments. BuySellSignals eschews "hot tip" or headline investing in favour of high-quality, ultra-current, targeted technical and fundamental information including specific bullish and bearish signals for each stock. Insights that will guide you to the investments that are hard to find in today's hyperactive mainstream markets.

For further details on definitions and quotations from investing legends, [Click here](#)

Disclaimer: While this document is based on information sources which are considered reliable, it has been prepared without consideration of your specific investment objectives, financial situation or needs, so you should carry out your own analysis or seek professional investment advice before an investment decision is made. The document contains unbiased, independent equities data from BuySellSignals (AFS Licence 222756) and News Bites Pty Ltd, who provide round the clock data on every Australian stock and sector. Neither BuySellSignals nor News Bites are brokers, and neither have an executing, corporate advisory or investment banking function. BuySellSignals and News Bites Pty Ltd, its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. The data is sourced from annual reports and company releases and may not be fully up to date. It should be used as a guide only.
